Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants

Critical Care

Volumn 21, Issue 1, 2017, Pages

  Ebner, Matthias ^a,b   Birschmann, Ingvild ^c   Peter, Andreas ^d,e   Spencer, Charlotte ^a   Härtig, Florian ^a   Kuhn, Joachim ^c   Blumenstock, Gunnar ^d   Zuern, Christine S ^d   Ziemann, Ulf ^a   Poli, Sven ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

Anticoagulation reversal; Direct oral anticoagulants; DOAC; Emergency surgery; NOAC; Non vitamin K antagonist oral anticoagulants; POCT; Point of care testing; Stroke; Thrombolysis

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; RIVAROXABAN; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ACTIVATED CLOTTING TIME; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; EMERGENCY TREATMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; POINT OF CARE TESTING; PROSPECTIVE STUDY; PROTHROMBIN TIME; RELIABILITY; SENSITIVITY AND SPECIFICITY; BLOOD CLOTTING TEST; CLINICAL TRIAL; DEVICES; POINT OF CARE SYSTEM; PROCEDURES; STANDARDS; THROMBIN TIME;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; DABIGATRAN; FACTOR XA INHIBITORS; HUMANS; PARTIAL THROMBOPLASTIN TIME; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; RIVAROXABAN; THROMBIN TIME;

EID: 85012897061     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-017-1619-z     Document Type: Article

References (28)

1. Rizos T, Herweh C, Jenetzky E, Lichy C, Ringleb PA, Hacke W, Veltkamp R. Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke. 2009;40(11):3547-51.
2. Ebner M, Peter A, Spencer C, Hartig F, Birschmann I, Kuhn J, Wolf M, Winter N, Russo F, Zuern CS, et al. Point-of-care testing of coagulation in patients treated with non-vitamin k antagonist oral anticoagulants. Stroke. 2015;46(10):2741-7.
3. Baruch L, Sherman O. Potential inaccuracy of point-of-care INR in dabigatran-treated patients. Ann Pharmacother. 2011;45(7-8):e40.
4. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012;125(4):417-20.
5. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11(8):1493-502.
6. Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, Friedman KD, Moll S. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost. 2014;111(6):1133-40.
7. Mani H, Herth N, Kasper A, Wendt T, Schuettfort G, Weil Y, Pfeilschifter W, Linnemann B, Herrmann E, Lindhoff-Last E. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit. 2014;36(5):624-31.
8. Kuhn J, Gripp T, Flieder T, Dittrich M, Hendig D, Busse J, Knabbe C, Birschmann I. UPLC-MRM mass spectrometry method for measurement of the coagulation inhibitors dabigatran and rivaroxaban in human plasma and its comparison with functional assays. PLoS One. 2015;10(12):e0145478.
9. Dincq AS, Lessire S, Douxfils J, Dogne JM, Gourdin M, Mullier F. Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. Biomed Res Int. 2014;2014:385014.
10. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)-March 2013. Arch Cardiovasc Dis. 2013;106(6-7):382-93.
11. CHMP assessment report Pradaxa. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000829/WC500110875.pdf. Accessed 16 Jan 2017.
12. Eikelboom JW, Weitz JI. Dabigatran monitoring made simple? Thromb Haemost. 2013;110(3):393-5.
13. Ward C, Conner G, Donnan G, Gallus A, McRae S. Practical management of patients on apixaban: a consensus guide. Thromb J. 2013;11(1):27.
14. Steiner T, Bohm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013;102(6):399-412.
15. Vassarstats: Website for Statistical Computation. http://vassarstats.net/clin1.html. Accessed 16 Jan 2017.
16. Evans JD. Straightforward statistics for the behavioral sciences. Pacific Grove: Brooks/Cole Publ. Co., an International Thomson Publ. Co.; 1996.
17. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625-51.
18. Eliquis, INN-apixaban: Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed 16 Jan 2017.
19. Pradaxa, INN-dabigatran: Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed 16 Jan 2017.
20. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675-86.
21. Jauch EC, Saver JL, Adams Jr HP, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan Jr PW, Qureshi AI, Rosenfield K, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947.
22. Godier A, Martin AC, Leblanc I, Mazoyer E, Horellou MH, Ibrahim F, Flaujac C, Golmard JL, Rosencher N, Gouin-Thibault I. Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations. Thromb Res. 2015;136(4):763-8.
23. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1128-39.
24. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23(2):138-43.
25. Tripodi A. The laboratory and the direct oral anticoagulants. Blood. 2013;121(20):4032-5.
26. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. 2013;34(7):489-498b.
27. Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, Wood P, McLintock C. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J. 2014;44(6):525-36.
28. Douxfils J, Tamigniau A, Chatelain B, Goffinet C, Dogne JM, Mullier F. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J. 2014;12:24.